Skip to Content

Qelbree (viloxazine) and Alcohol / Food Interactions

There is 1 alcohol/food/lifestyle interaction with Qelbree (viloxazine):


Caffeine viloxazine

Moderate Drug Interaction

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with potent CYP450 1A2 inhibitors such as fluvoxamine may increase the plasma concentrations of caffeine in a dose-dependent manner. Caffeine is primarily metabolized by CYP450 1A2 and is considered a probe substrate for the isoenzyme. In 12 healthy volunteers, pretreatment with fluvoxamine for 7 days (10 mg once or twice a day) resulted in a 2-fold increase in the mean 24-hour area under the plasma concentration-time curve (AUC) of a single 100 mg oral dose of caffeine. When the dosage of fluvoxamine was increased (25 mg once or twice a day for 7 days), the mean 24-hour AUC of single-dose caffeine increased 5-fold. The peak plasma concentration (Cmax) of caffeine increased 40% and 141%, respectively, during these treatment phases. Another study found that fluvoxamine (50 mg daily for 4 days, then 100 mg daily for 8 days) decreased the median total clearance of a single 200 mg oral dose of caffeine by 80% and increased the half-life from 5 to 31 hours in eight healthy volunteers.

MANAGEMENT: Caution is advised if caffeine is administered concurrently with potent CYP450 1A2 inhibitors. Dosage adjustment should be considered in patients who experience excessive adverse effects of caffeine such as nausea, vomiting, headache, nervousness, irritability, agitation, restlessness, insomnia, tinnitus, tremors, and tachycardia.


  1. Jeppesen U, Loft S, Poulsen HE, Brosen K "A fluvoxamine-caffeine interaction study." Pharmacogenetics 6 (1996): 213-22
  2. Christensen M, Tybring G, Mihara K, et al. "Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19)." Clin Pharmacol Ther 71 (2002): 141-52
  3. Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S "Fluvoxamine is a potent inhibitor of cytochrome P4501A2." Biochem Pharmacol 45 (1993): 1211-4

Qelbree (viloxazine) drug interactions

There are 231 drug interactions with Qelbree (viloxazine)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.